4D Molecular Therapeutics Inc
NASDAQ:FDMT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Balance Sheet
Balance Sheet Decomposition
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
Balance Sheet
4D Molecular Therapeutics Inc
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
24
|
92
|
50
|
277
|
153
|
52
|
249
|
149
|
|
| Cash Equivalents |
24
|
92
|
50
|
277
|
153
|
52
|
249
|
149
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
95
|
161
|
39
|
276
|
|
| Total Receivables |
0
|
1
|
1
|
2
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
1
|
1
|
2
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
2
|
4
|
9
|
7
|
8
|
10
|
|
| Total Current Assets |
25
|
94
|
53
|
283
|
256
|
221
|
297
|
435
|
|
| PP&E Net |
3
|
3
|
5
|
5
|
29
|
35
|
32
|
41
|
|
| PP&E Gross |
3
|
3
|
5
|
5
|
29
|
35
|
32
|
41
|
|
| Accumulated Depreciation |
1
|
2
|
3
|
4
|
5
|
8
|
12
|
17
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
68
|
5
|
11
|
81
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
4
|
|
| Total Assets |
27
N/A
|
97
+255%
|
58
-40%
|
288
+395%
|
354
+23%
|
262
-26%
|
340
+30%
|
560
+65%
|
|
| Liabilities | |||||||||
| Accounts Payable |
1
|
1
|
2
|
2
|
5
|
3
|
4
|
4
|
|
| Accrued Liabilities |
1
|
2
|
3
|
5
|
7
|
10
|
14
|
22
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
5
|
6
|
8
|
10
|
4
|
2
|
2
|
3
|
|
| Total Current Liabilities |
6
|
8
|
13
|
17
|
16
|
16
|
19
|
29
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
23
|
14
|
15
|
15
|
18
|
15
|
13
|
21
|
|
| Total Liabilities |
28
N/A
|
22
-24%
|
28
+31%
|
32
+13%
|
34
+8%
|
31
-11%
|
32
+5%
|
50
+55%
|
|
| Equity | |||||||||
| Common Stock |
19
|
103
|
103
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
21
|
30
|
79
|
136
|
207
|
315
|
415
|
576
|
|
| Additional Paid In Capital |
1
|
2
|
6
|
392
|
527
|
547
|
723
|
1 087
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Equity |
1
N/A
|
75
N/A
|
30
-60%
|
256
+755%
|
319
+24%
|
231
-28%
|
308
+33%
|
511
+66%
|
|
| Total Liabilities & Equity |
27
N/A
|
97
+255%
|
58
-40%
|
288
+395%
|
354
+23%
|
262
-26%
|
340
+30%
|
560
+65%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
5
|
5
|
5
|
27
|
32
|
33
|
43
|
46
|
|
